Using PML nuclear body biology to identify potential AML treatment targets

Project description

Understanding PML nuclear bodies disruption in the context of AML treatment

Fields of science

• natural sciences › biological sciences › genetics › DNA
• natural sciences › biological sciences › genetics › mutation
• medical and health sciences › clinical medicine › oncology › leukemia
• natural sciences › chemical sciences › analytical chemistry › mass spectrometry

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Net EU contribution

€ 184 707,84

Address

Rue De Tolbiac 101
75654 Paris
France

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Other funding

€ 184 707,84